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7RESEARCH ARTICLE Open AccessCharacterization of Neisseria gonorrhoeae isolates
detected in Switzerland (1998–2012): emergence
of multidrug-resistant clones less susceptible to
cephalosporins
Andrea Endimiani1*, Yuvia N Guilarte1, Regula Tinguely1, Lea Hirzberger1,2, Sylvia Selvini1, Agnese Lupo1,
Christoph Hauser2 and Hansjakob Furrer2Abstract
Background: The spread of Neisseria gonorrhoeae (Ng) isolates resistant to the clinically implemented antibiotics is
challenging the efficacy of treatments. Unfortunately, phenotypic and molecular data regarding Ng detected in
Switzerland are scarce.
Methods: We compared the characteristics of Ng detected during 1998–2001 (n = 26) to those detected during
2009–2012 (n = 34). MICs were obtained with the Etest and interpreted as non-susceptible (non-S) according to
EUCAST criteria. Sequence type (ST) was achieved implementing the NG-MAST. BlaTEM, ponA, penA, mtrR, penB, tet
(M), gyrA, parC, mefA, ermA/B/C/F, rplD, rplV, and 23S rRNA genes were analyzed.
Results: The following susceptibility results were obtained (period: % of non-S, MIC90 in mg/L): penicillin (1998–2001:
42.3%, 3; 2009–2012: 85.3%, 16), cefixime (1998–2001: 0%, ≤0.016; 2009–2012: 8.8%, 0.125), ceftriaxone (1998–2001: 0%,
0.004; 2009–2012: 0%, 0.047), ciprofloxacin (1998–2001: 7.7%, 0.006; 2009–2012: 73.5%, ≥32), azithromycin (1998–2001:
11.5%, 0.25; 2009–2012: 23.6%, 0.38), tetracycline (1998–2001: 65.4%, 12; 2009–2012: 88.2%, 24), spectinomycin (1998–2001:
0%, 12; 2009–2012: 0%, 8). The prevalence of multidrug-resistant (MDR) isolates increased from 7.7% in 1998–2001 to
70.6% in 2009–2012. International STs and genogroups (G) emerged during 2009–2012 (G1407, 29.4%; G2992, 11.7%;
G225, 8.8%). These isolates possessed distinctive mechanisms of resistance (e.g., G1407: PBP1 with L421, PBP2 pattern
XXXIV, GyrA with S91F and D95G, ParC with S87R, PorB with G120K and A121N, mtrR promoter with A deletion).
Conclusions: The prevalence of penicillin- ciprofloxacin- and tetracycline-resistant Ng has reached dramatic levels,
whereas cefixime and ceftriaxone show MICs that tend to increase during time. International MDR clones less susceptible
to cephalosporins are rapidly emerging indicating that the era of untreatable gonococcal infections is close.
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Neisseria gonorrhoeae (Ng) is the etiologic agent of the
second most common sexually transmitted infection
(STI) globally [1]. The number of gonococcal infections
is rapidly increasing, especially because subjects are
often asymptomatic. This condition contributes to the
spread of the pathogen, but also to the silent progression
of the infection to more serious clinical conditions as* Correspondence: aendimiani@gmail.com
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unless otherwise stated.the pelvic inflammatory diseases. Therefore, along with
the implementation of effective preventive strategies, the
administration of adequate antibiotic treatments can
contribute to the control of infections [2,3].
Unfortunately, Ng has a remarkable ability to develop
resistance to all of the clinically implemented antibiotics
[4]. In brief, resistance to ciprofloxacin (CIP) is usually
due to amino acid substitutions in GyrA and ParC [5,6].
Azithromycin (AZT) can become inactive due to muta-
tions in the four copies of the 23S rRNA, production
of methylase enzymes encoded by acquired genes (e.g.,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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proteins [5,7]. Tetracycline (TET) is usually ineffective
because of tet(M) gene acquisition [3,5]. Resistance to
penicillin (PEN) is due to production of acquired TEM-
1-like β-lactamases or alterations of the penicillin bind-
ing proteins (PBPs; e.g., amino acid substitutions for
PBP1 and PBP2) [3,4,8]. Notably, the over-expression of
the MtrCDE efflux pump due to substitutions in its
repressor MtrR or deletions/insertions in the mtr pro-
moter region may reduce susceptibility to all of the
above mentioned drugs [5,9], whereas substitutions in
the PorB outer membrane porin may affect PEN and
TET [10].
However, the most threatening global concern is rep-
resented by the recent emergence of Ng isolates resist-
ant to cefixime (CFX) and, even more importantly, to
ceftriaxone (CRO) [11-15]. Reduced susceptibility to
these cephalosporins can be due to a mixture of the
mechanisms involved in penicillin resistance, but full
resistance necessitates specific mosaic structures of
the PBP2 that are caused by recombination events
occurring between gonococcus and other commensal
Neisseria species [4,16,17].
Taking into account these clinical problems, and based
on national and international guidelines [2,18], many
countries have recently established active surveillance
programs to monitor the evolution of antimicrobial
susceptibility for Ng isolates [3,19-22], and the spread
of international clones (e.g., sequence types ST1407,
ST2992, and ST225) that are usually more resistant
[8,13,19,23,24]. Clinical treatment and public health
strategies for controlling gonococcal STI clearly benefit
from the combined availability of these data [2,3]. How-
ever, we should note that there is a need of this compul-
sory information for our country. Thus, in the present
work, we investigated the phenotypic and molecular
characteristics of Ng isolates detected in Switzerland
during a 15-year period.Methods
Clinical isolates
We analyzed the Ng isolates collected by the Labora-
tory of Clinical Microbiology of the University of Bern
(Switzerland) during a 15-year period and isolated
implementing standard microbiological methodologies
[25]. The characteristics of isolates detected during
1998–2001 (n = 26) were compared to those of gono-
cocci detected during 2009–2012 (n = 34). Strains had
been stored at −80°C over the time in glycerol stock
tubes (Almedica AG). For the present study, isolates
were plated on GC agar (bioMérieux) and species iden-
tification was confirmed by using the MALDI-TOF MS
(Bruker Daltonik).Antimicrobial susceptibility tests (ASTs)
Minimum inhibitory concentrations (MICs) for PEN,
CFX, CRO, CIP, AZT, TET, spectinomycin (SPE) and
gentamicin (GEN) were obtained using the Etest method
on GC agar plates. Results were categorized according
to the 2013 European Committee on Antimicrobial
Susceptibility Testing (EUCAST) criteria [26]. Produc-
tion of β-lactamases was evaluated by implementing
the cefinase disk (Oxoid) and also mixing 5 μL of β-
lactamase(s) extract with 50 μL of nitrocefin [100 μM]
for 1 hour. N. gonorrhoeae ATCC 49226 and Staphylo-
coccus aureus ATCC 29213 were used as controls.
Analysis of clonality
Sequence type (ST) designation was achieved by analyz-
ing both por and tbpB genes according to the Neisseria
gonorrhoeae Multi-Antigen Sequence Typing method-
ology (NG-MAST; http://www.ng-mast.net/) [27]. STs
were clustered in genogroups (e.g., G1407, G2992, and
G225) whenever possible, as previously done [23].
Molecular characterization of drug resistance genes
Genomic extraction was performed using the QIAmp
DNA mini kit (QIAGEN). The following antibiotic re-
sistance genes (and their encoded proteins) were ana-
lyzed as previously described [5]: ponA (PBP1), penA
(PBP2), blaTEM (β-lactamases), gyrA and parC (quin-
olone resistance determining region), penB (PorB porin),
mtrR and mtrR promoter (MtrCDE efflux pump), rplD
and rplV (ribosomal protein L4 and L22, respectively),
the four 23S rRNA gene copies, mefA (efflux-mediated
resistance mechanism), ermA/B/C/F (methylase enzymes),
and tet(M) (ribosomal protection protein). DNA sequen-
cing was performed in service by Eurofins (Ebersberg,
Germany) and chromatogram traces were analyzed using
DNAStar (Lasergene). Results for all of the above genes
were analyzed by searching for homologies with BLAST
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) or by comparison
with the following deposited wild-type alleles: ponA,
penB, mtrR and mtrR promoter, gyrA, parC, rplD, and
rplV (GenBank: AE004969); penA (GenBank: M32091);
blaTEM-1 (GenBank: AJPQ01000032); and 23S rRNA
(GenBank: CP001050).
Results
Clinical isolates
Ng isolates collected during 1998–2001 were from 18
males (median age 26.5; range 0–37 years) and 8 females
(median age 26.0; range 16–40 years), whereas those col-
lected during 2009–2012 were from 30 males (median age
33.0; range 21–56 years) and 4 females (median age 25.0;
range 23–49 years). In 1998–2001, samples from males
were urethral (n = 17) and ocular swabs (n = 1), whereas
those from females were cervical (n = 4), vaginal (n = 2),
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gard to 2009–2012, samples from males were urethral (n =
29) and pharyngeal swabs (n = 1), whereas those from
females were vaginal (n = 3) and abscess swabs (n = 1).Figure 1 MIC values distribution for the eight antibiotics tested again
(1998–2001 versus 2009–2012). “S”, indicates the cut-off of susceptibility,
to the EUCAST criteria [26]. The results clearly show that the MICs for ceph
to 0.047 mg/L; CFX: from MIC90≤ 0.016 to 0.125 mg/L with also 8.8% of th
TET-resistant isolates reached dramatic levels.Antimicrobial susceptibility
The MIC distributions for the eight antibiotics tested
against Ng isolates detected during the two different
periods are shown in Figure 1.st the Ng isolates detected during the two different periods
whereas “R” indicates the isolates intermediate or resistant according
alosporins increased over time (i.e., CRO: from MIC90 of 0.004 mg/L
e isolates resistant) and that the prevalence of PEN-, CIP-, and
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markable increase in resistance to PEN (from 42.3% to
85.3%) and CIP (from 7.7% to 73.5%), but also a marked
rise in resistance to AZT (from 11.5% to 23.6%) and
TET (from 65.4% to 88.2%). With regard to cephalospo-
rins, we noted a rise in the MIC values for both CFX
(from MIC90 ≤ 0.016 mg/L to MIC90 of 0.125 mg/L, with
8.8% of resistant isolates) and CRO (from MIC90 of
0.004 mg/L to MIC90 of 0.047 mg/L). Only SPE (all 60
isolates were susceptible) and GEN did not show in-
creased MICs (Figure 1).
As shown in Table 1, the prevalence of multidrug-
resistant (MDR) isolates (i.e., those resistant to ≥ 3 anti-
biotic classes [4]) increased from 7.7% in 1998–2001 to
70.6% in 2009–2012. We also noted that the isolates
simultaneously resistant to four antibiotics augmented from
3.8% in 1998–2001 to 26.5% in 2009–2012, whereas those
resistant to five antimicrobials (PEN, CIP, AZT, TET, and
CFX) reached 5.9% in 2009–2012.Clonality
Sequencing types (STs) of Ng isolates detected during
1998–2001 and 2009–2012 are summarized in Figure 2.Table 1 Patterns of antimicrobial and associated
resistances of the N. gonorrhoeae isolates detected in
Switzerland during the study perioda
Antibioticsb No. and (%) of isolates
1998-2001
(n = 26)
2009-2012
(n = 34)
Resistant to≥ 2 antibiotics: 14 (53.8) 31 (91.2)
-PEN and CIP 2 (7.7) 25 (73.5)
-PEN and AZT 3 (11.5) 8 (23.5)
-PEN and TET 14 (53.8) 28 (82.4)
-CIP and TET 2 (7.7) 23 (67.6)
-CIP and AZT 1 (3.8) 7 (20.6)
-AZT and TET 3 (11.5) 8 (23.5)
Resistant to≥ 3 antibiotics (i.e., MDR isolates): 2 (7.7) 24 (70.6)
-PEN, CIP, and AZT 1 (3.8) 7 (20.6)
-PEN, CIP, and TET 2 (7.7) 23 (67.6)
-PEN, AZT, and TET 3 (11.5) 8 (23.5)
-CIP, AZT, and TET 1 (3.8) 7 (20.6)
Resistant to≥ 4 antibiotics: 1 (3.8) 9 (26.5)
-PEN, CIP, AZT, and TET 1 (3.8) 7 (20.6)
-PEN, CIP, TET, and CFX 0 (0.0) 2 (5.9)
Resistant to 5 antibiotics (PEN, CIP, AZT, TET,
and CFX)
0 (0.0) 2 (5.9)
Note. PEN, penicillin; CIP, ciprofloxacin; AZT, azithromycin; TET, tetracycline;
CFX, cefixime.
aAll isolates were susceptible to ceftriaxone (CRO) and spectinomycin (SPE).
b“Resistant” includes intermediate and resistant according to the EUCAST
criteria [26].In 1998–2001, only the international genogroup G25
was identified (one ST25 in 1998 and one ST3369 in
2001). In contrast, during 2009–2012 the international
lineages G1407 (29.4%), G2992 (11.7%), and G225 (8.8%)
were detected. Most of these hyperepidemic genogroups
were MDR (e.g., 9/10 of the isolates of G1407 were resist-
ant to ≥ 3 antibiotics). Moreover, Ng of G1407 possessed
the highest MICs for CFX and CRO, with MIC50/90 of
0.125/0.19 mg/L and MIC50/90 of 0.032/0.047 mg/L, re-
spectively (data not fully shown; see also Table 2).
Drug resistance genes
The specific phenotypic and molecular characteristics of
Ng detected during 2010–2012 (n = 26) are presented in
Table 2.
Isolates with reduced susceptibility to antibiotics pos-
sessed the following specific antibiotic resistance traits:
PBP1 (substitution L421P), PBP2 (mosaics II, V, XII, XIX,
or XXXIV), TEM-1-like β-lactamases, GyrA (substitutions
S91F, D95G, and D95A), ParC (substitutions S87R and
E91G), PorB (substitutions G120K and A121D/N/G), MtrR
(substitutions A39T, R44H, G45D, L47P), mtrR promoter
(A deletion), and the Tet(M) protective protein. RplD, rplV
and 23S rRNA genes did not present mutations and erm
or mefA genes were not detected.
Notably, Ng isolates belonging to G1407, G2992, and
G225 constantly possessed specific and conserved anti-
biotic resistance patterns (e.g., all G1407 had PBP1 with
L421P, PBP2 pattern XXXIV, GyrA with S91F and D95G,
ParC with S87R, PorB with G120K and A121N, and the A
deletion in the mtrR promoter region).
Discussion
Programs monitoring the antibiotic susceptibility of Ng
are essential to implement adequate empirical treatments
[1,3,18,20]. Information about the underlying molecular
mechanisms of resistance is equally important to design
and evaluate new rapid diagnostic systems [30]. Moreover,
the incidence of Ng hyperepidemic clones should be care-
fully monitored because these isolates have the potential
to spread quickly and are showing increasing resistance to
most of the clinically used antibiotics [13,19,23].
In 2008, Le Lin et al. described the emergence (2002)
of Ng resistant to CIP in Geneva [31]. Very recently,
Kovari et al. have analyzed the susceptibility to four anti-
biotics (CFX, CRO, CIP and PEN) of 320 isolates col-
lected in 1990 and from 2000 to 2012 at the University
of Zurich [32]. However, up to now surveys studying the
molecular characteristics, especially the clonality, of Ng
detected in Switzerland have not yet been performed.
Therefore, the aim of the present work was to fill up the
lack of contemporary data regarding gonococcus imple-
menting the methodologies suggested by the acknowl-
edged international institutions [19,20].
Figure 2 Sequencing types (STs) of the Ng isolates detected during the two different periods (1998–2001 and 2009–2012). STs with
more than one isolate are indicated in colors and with their percentages. Hyperepidemic clones are indicated in bold and STs included in the
same genogroup (G) are underlined. The results show that international lineages reported in other countries (G1407, G2992, and G225) are also
emerging and spreading in Switzerland. With the exception of two isolates of G25, these STs/Gs were not present during the previous decade.
Notably, most of the hyperepidemic clones were MDR (i.e., resistant to≥ 3 antibiotics).
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Consistently with the study of Kovari et al. [32], our
phenotypic data indicate that the prevalence of Ng resist-
ant to either PEN or CIP increased considerably during
the last decade (>73%). However, in our study we have
also observed that the occurrence of isolates simultan-
eously resistant to PEN, CIP, and TET has reached a
dramatic level (68%). These figures clearly show that the
use of these three antibiotics for the empirical treatment
of gonococcal infections is no longer safe. This phe-
nomenon is not new and has been observed in other
countries. The extensive use of antibiotic treatments
without performing the ASTs has generated not only
an escalation of “treatment failures” [33-36], but also a
positive selective pressure for specific international
MDR clones (e.g., G1407 and G225) [3,4].
Fortunately, current Ng isolates spreading in Switzerland
seem to remain susceptible to the standard therapeutic
option CRO [32,37]. However, its MICs are increasing
over time (“MIC creep”) as observed worldwide [3,4,20],
and one should be aware that CRO-resistant isolates
can emerge and spread [4,7,11,12,14,17]. This possibledevelopment could also be favored by the observed de-
creased susceptibility to AZT, an antibiotic used together
with CRO to cover Chlamydia trachomatis co-infections
and more recently also implemented to prevent treatment
failures of gonococcal infections [33,37]. In this overall
scenario, we noted that all Ng tested were susceptible to
SPE, probably because the use of this antibiotic has
been abandoned after observing outbreaks of resistant
isolates in the 1980s [3,4]. SPE-resistant Ng are now
rarely reported [20,21], and this antibiotic could be
reconsidered - along with gentamicin - for the treat-
ment of infections due to MDR isolates showing co-
associated reduced susceptibility to CRO and AZT [4].
Emergence of successful international STs and
genogroups
The NG-MAST analysis pointed out that in the last
few years the G1407, G2992, and G225 international
genogroups have also reached Switzerland, now represent-
ing ~50% of the overall isolates. Most likely, these
lineages were initially imported by infected people who
had sexual intercourse abroad, but it is difficult to
Table 2 Phenotypic and molecular characteristics (clonality and drug resistance genes) of 26N. gonorrhoeae isolates detected during the period 2010–2012 in
Switzerland
Isolate Year ST
(Genogroup)
PPa Minimum inhibitory concentration, mg/Lb PBP1
(ponA)
PBP2 (penA)c TEM GyrA ParC PorB
(penB)
MtrR mtrR
promoter
L4
(rplD)
L22
(rplV)
23S rRNA
(4 copies)
ermA/
B/C/F
and
mefA
tet
(M)
PEN CFX CRO CIP AZT TET SPE GEN
1820606 2010 495 + 6 ≤0.016 0.006 0.006 0.38 96 12 8 L421P XII TEM-1 WT WT G120K,
A121D
A39T,
L47P
WT WT WT All WT - +
1865296 2010 292 - 0.25 ≤0.016 0.006 2 0.25 0.5 6 4 L421P V - S91F, D95G S87R A121S WT A
deletion
WT WT All WT - -
1872778 2010 2861 (G225) - 0.38 0.047 0.032 >32 0.25 0.75 4 4 L421P XII - S91F, D95G S87R G120K,
A121D
WT A
deletion
WT WT All WT - -
1832086 2010 1407 (G1407) - 0.5 0.19 0.047 6 0.25 1.5 8 6 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
1859198 2010 225 (G225) - 0.5 0.047 0.032 >32 0.38 1.5 8 8 L421P XII - S91F, D95G S87R G120K,
A121D
WT A
deletion
WT WT All WT - -
1910312 2010 2992 (G2992) - 0.094 ≤0.016 0.003 ≤0.002 0.25 0.38 6 4 WT II - WT WT WT A39T,
R44H
WT WT d WT All WT - -
1869994 2010 1766 + 6 ≤0.016 0.006 0.75 ≤0.016 6 6 4 L421P IIg TEM-1 S91F, D95A S87N G120D WT A
deletion
WT WT All WT - +
1912168 2010 8676 + 32 ≤0.016 ≤0.002 3 0.032 8 4 4 L421P II TEM-1 S91F, D95G S87R G120K,
A121D
WT WT WT WT All WT - +
1922603 2011 3149 (G1407) - 0.38 0.19 0.047 16 0.25 1.5 8 6 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
1996003 2011 3611 + 12 ≤0.016 0.008 >32 0.125 96 8 4 L421P XIX TEM-1 S91F, D95A S87N,
E91K
G120K,
A121G
A39T WT WT WT All WT - +
2017570 2011 1407 (G1407) - 0.38 0.125 0.023 12 0.38 1 8 6 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
2004277 2011 8708 - 0.125 ≤0.016 ≤0.002 ≤0.002 0.25 0.5 8 4 WT II - WT WT WT G45D WT WT WT All WT - -
1973517 2011 4232 - 0.19 ≤0.016 0.003 ≤0.002 0.19 16 8 6 WT II - WT WT A121S G45D WT WT d WT All WT - +
1929711 2011 2992 (G2992) - 0.064 ≤0.016 0.003 ≤0.002 0.25 0.38 8 6 WT II - WT WT WT A39T,
R44H
WT WT d WT All WT - -
1944251 2011 2992 (G2992) - 0.047 ≤0.016 0.003 ≤0.002 0.25 0.25 6 4 WT II - WT WT WT A39T,
R44H
WT WT d WT All WT - -
1954615 2011 8707 + 12 ≤0.016 0.004 1.5 0.064 24 2 4 L421P XIX TEM-1 S91F, D95A S87R A121S A39T WT WT WT All WT - +
1946253 2011 1407 (G1407) - 0.38 0.125 0.032 32 0.75 1.5 8 6 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
2036196 2012 5528 + >32 ≤0.016 0.004 12 0.25 64 8 4 WT II TEM-
135
S91F, D95G D86N G120K,
A121D
WT WT WT WT All WT - +
2086772 2012 8827 + 3 ≤0.016 ≤0.002 2 0.023 16 6 6 L421P XIX TEM-1 S91F, D95A S87N,
E91K
G120K,
A121D
A39T WT WT WT All WT - +
2096513 2012 7616 - 0.047 ≤0.016 0.002 ≤0.002 0.25 0.38 6 8 WT II - WT WT WT A39T,
R44H
WT WT d WT All WT - -
2112655 2012 8826 - 0.38 0.094 0.023 24 0.125 0.25 3 6 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
2119347 2012 3378 - 0.38 0.094 0.032 16 0.5 1 8 12 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
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Table 2 Phenotypic and molecular characteristics (clonality and drug resistance genes) of 26N. gonorrhoeae isolates detected during the period 2010–2012 in
Switzerland (Continued)
2121127 2012 8825 - 0.125 ≤0.016 0.003 0.75 ≤0.016 0.25 2 1 L421P II - S91F, A92S,
D95N
E91G G120K,
A121D
A39T WT WT WT All WT - -
2129562 2012 437 (G225) - 0.25 0.023 0.023 24 0.19 0.5 3 8 L421P V - S91F, D95G S87R G120K,
A121D
WT A
deletion
WT WT All WT - -
2131245 2012 8410 + 16 0.023 0.006 3 0.064 8 8 6 WT XXI-like TEM-
135
S91F, D95A S87R A121G A39T WT WT WT All WT - +
2132307 2012 3149 (G1407) - 0.38 0.094 0.023 32 0.38 1 8 8 L421P XXXIV - S91F, D95G S87R G120K,
A121N
WT A
deletion
WT WT All WT - -
Note. WT, wild-type; +, positive; −, negative.
aPenicillinase producers according to the cefinase disk test (Oxoid) and nitrocefin test.
bAbbreviations and MIC interpretation according to the EUCAST criteria [26]: penicillin (PEN; sensible, S ≤ 0.06 mg/L); ceftriaxone (CRO; S ≤ 0.125 mg/L); cefixime (CFX; S ≤ 0.125 mg/L); ciprofloxacin (CIP; S ≤ 0.03 mg/L);
azithromycin (AZT; S ≤0.25 mg/L); tetracycline (TET; S ≤ 0.25 mg/L); spectinomycin (SPE; S ≤ 64 mg/L); gentamicin (GEN; criteria not available).
cThe characteristics of the PBP2 patterns II, V, XII, and XIX were described by Whiley DM et al. [16], those of pattern XXXIV by Hess D et al. [28], and pattern IIg by Takahashi et al. [29]. Pattern XXI-like does not
have -574N and A575V as in the XXI [16].
dThe L4 of these Ng isolates possessed three substitutions (i.e., V125A, A147G, R157Q) that have no recognized impact on the macrolides resistance.
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http://www.biomedcentral.com/1471-2334/14/106hypothesize which countries were most responsible for
this phenomenon. In fact, G1407 is currently the most fre-
quently detected genogroup worldwide (e.g., 23% of the
isolates in Europe), whereas G225 and G2992 are second
and third (e.g., 10% and 8% in Europe, respectively) [23].
For instance, ST1407 is first in rank in countries like
Austria, Italy, the Netherlands, Portugal, Spain, Romania,
Slovenia, United Kingdom, Japan and Canada; ST2992 is
very frequent in Ireland and Norway; and ST225 is pre-
dominant in Malta and Denmark [19,21,24,38].
As also observed in this work, G1407 and G225 are con-
stantly characterized by fully resistance to CIP and reduced
susceptibility (at intermediate level) to PEN, AZT, and TET,
whereas G2992 is usually pan-susceptible [3]. G1407 has
also decreased susceptibility to CFX and, to a lesser extent,
to CRO [4,21,28]. In this context, we note that most of the
previously reported CFX or CRO treatment failures were
due to Ng isolates of G1407 [4,11,12,39].
Drug resistance genes
Due to the number and complexity of the mechanisms
[5], we decided to analyze only the main molecular traits
of resistance possessed by the Ng isolates found during
2010–2012 (Table 2).
Isolates of G1407 were slightly resistant to PEN because
of L421P in PBP1, overexpression of MtrCDE efflux by one
A deletion in the promoter, and reduced permeability of
PorB (substitutions G120K and A121N). However, they
also showed augmented MICs to CFX and CRO due to
the presence of the mosaic XXXIV [4,8,21,28,36,38].
This PBP2 variant may predispose the clone to become
highly-resistant to CRO [11,12]. Similarly, G2992 and
G225 tested intermediate to PEN, but were fully suscep-
tible to cephalosporins because of the presence of PBP2
mosaics (i.e., II, V, XII, and XIX) that have little effects
against CFX and CRO [16]. These commonly reported
PBP2 mosaics were also present in the fully cephalosporin-
susceptible Ng belonging to sporadic STs.
Non-hyperepidemic isolates were frequently TEM-1 pro-
ducers but two of them expressed the TEM-135, a TEM-1
variant (substitution M182T) previously reported only in
Japan, Thailand, and China [8,40,41]. TEM-135 is a
plasmid-mediated enzyme that does not hydrolyze CFX
and CRO, but its emergence might represent an inter-
mediate stage of the traditional TEM-1 penicillinase
into an extended-spectrum β-lactamase (ESBL) that is
able to confer high-level resistance to all β-lactams with
the exception of carbapenems [4]. Since this was not a
prospective clinical study, we are unable to provide in-
formation about the travel history of the two patients
infected by TEM-135 producers.
None of the Ng tested possessed acquired genes (erm,
mefA) or chromosomal mutations (23S rRNA, rplD, rplV)
conferring high-level resistance to macrolides [5,7].However, several isolates (including some of G1407 and
G225) were non-susceptible to AZT (MICs of 0.38-
0.75 mg/L). This phenomenon may be due to a feeble over-
expression of the MtrCDE efflux induced by the A deletion
in the mtrR promoter [5,9,42]. Finally, almost all CIP-
resistant Ng possessed well-known substitutions in GyrA
(amino acids 91 and 95) and ParC (amino acid 87). In par-
ticular, we highlight that the S91F replacement in GyrA
was constantly observed, making it a good single target
candidate for the molecular tests functional to categorize
Ng as resistant or susceptible to quinolones [6]. The imple-
mentation of a rapid bedside molecular test for CIP resist-
ance would allow treatment of infections due to susceptible
isolates with this drug and could reduce the selective pres-
sure on CRO in about 25% of gonorrhea in our country
while still maintaining good clinical efficacy.
Conclusions
This is the first study describing clonality and molecular
mechanisms of resistance of gonococcal isolates detected
in Switzerland. In this survey, we also analyzed the
changes in characteristics of Ng strains detected in the
same geographic area and during the last 15 years. We
note that studies focusing on these epidemiological tem-
poral trends are still limited but extremely important to
comprehend the spread and the evolution of antibiotic
resistance in Ng [3,20,22,32].
Overall, our data clearly indicate that the antibiotic
susceptibility of contemporary Ng isolates is dramatically
decreasing, mainly due to the spread of international
MDR clones that also show reduced susceptibility to the
standard therapeutic options CRO and AZT [37]. These
specific clones (e.g., ST1407 and its genogroups) are pre-
disposed to become more resistant representing the last
evolutionary step of the pathogen before the era of
extensively and pandrug-resistant isolates [4]. In this
context, we emphasize the urgent need of: i) rapid mo-
lecular tests able to provide adequate information to se-
lect the most appropriate direct antibiotic treatment
[30]; ii) novel antimicrobial families against molecular
targets not yet affected by resistance mechanisms [4]; iii)
increasing numbers of cultures to study and monitor
clonality and resistance mechanisms of gonococcus [4].
One limitation of the present study is that the survey
was performed in a single institution, was not prospect-
ive, and included a relative small number of Ng isolates.
However, we believe that our results may be representative
for the whole country because distances in Switzerland are
very short and our institution is located in the middle of
the territory. In support of this speculation, we note that
our phenotypic data are consistent with those recently pro-
vided by the larger analysis performed in Zurich [32].
To provide more robust and systematic data that are
essential for controlling the rapidly increasing number of
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tional surveillance monitoring program - supported by
the state public institutions - should be established rap-
idly and before our health care systems dramatically face
the attack of untreatable gonococcal isolates [4,17].
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AE: study design, results interpretation, and writing manuscript; YNG:
molecular characterization, species identification, phenotypic tests; RT:
molecular characterization; LH: molecular characterization and phenotypic tests;
SS: species identification, phenotypic tests; AL: molecular characterization and
reviewing manuscript; CH: reviewing manuscript; HF: study design and reviewing
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank Selina Hutter and Salome N. Seiffert for helping with phenotypic
tests and molecular analyses and Sara Droz for providing clinical isolates. This
work was supported by internal funds of the Institute for Infectious Diseases
and the Department of Infectious Diseases, Bern University Hospital. The
study was also partially supported by a grant from the Bern University
Hospital, Inselspital (CH, HF, and AE).
Author details
1Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
2Department of Infectious Diseases, Bern University Hospital and University
of Bern, Bern, Switzerland.
Received: 29 November 2013 Accepted: 20 February 2014
Published: 25 February 2014
References
1. World Health Organization (WHO): Department of Reproductive Health and
Research. Global incidence and prevalence of selected curable sexually
transmitted infections - 2008. Geneva, Switzerland: WHO; 2012.
2. World Health Organization (WHO): Department of Reproductive Health and
Research. Global action plan to control the spread and impact of antimicrobial
resistance in Neisseria gonorrhoeae. Geneva, Switzerland: WHO; 2012.
3. Ison CA, Alexander S: Antimicrobial resistance in Neisseria gonorrhoeae in
the UK: surveillance and management. Expert Rev Anti Infect Ther 2011,
9(10):867–876.
4. Unemo M, Nicholas RA: Emergence of multidrug-resistant, extensively
drug-resistant and untreatable gonorrhea. Future Microbiol 2012,
7(12):1401–1422.
5. Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L,
Lo S, Low DE, Melano RG: Molecular analysis of antimicrobial resistance
mechanisms in Neisseria gonorrhoeae isolates from Ontario. Canada.
Antimicrob Agents Chemother 2011, 55(2):703–712.
6. Zhao L, Zhao S: TaqMan real-time quantitative PCR assay for detection of
fluoroquinolone-resistant Neisseria gonorrhoeae. Curr Microbiol 2012,
65(6):692–695.
7. Chisholm SA, Dave J, Ison CA: High-level azithromycin resistance occurs in
Neisseria gonorrhoeae as a result of a single point mutation in the 23S
rRNA genes. Antimicrob Agents Chemother 2010, 54(9):3812–3816.
8. Chen SC, Yin YP, Dai XQ, Yu RX, Han Y, Sun HH, Ohnishi M, Unemo M,
Chen XS: Prevalence and molecular epidemiological typing of penicillinase-
producing Neisseria gonorrhoeae and their blaTEM-135 Gene Variants in
Nanjing. China. Sex Transm Dis 2013, 40(11):872–876.
9. Warner DM, Shafer WM, Jerse AE: Clinically relevant mutations that cause
derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump
system confer different levels of antimicrobial resistance and in vivo
fitness. Mol Microbiol 2008, 70(2):462–478.
10. Shafer WM, Folster JP: Towards an understanding of chromosomally
mediated penicillin resistance in Neisseria gonorrhoeae: evidence for a
porin-efflux pump collaboration. J Bacteriol 2006, 188(7):2297–2299.
11. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C:
Molecular characterization of two high-level ceftriaxone-resistantNeisseria gonorrhoeae isolates detected in Catalonia. Spain. J Antimicrob
Chemother 2012, 67(8):1858–1860.
12. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P:
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in
France: novel penA mosaic allele in a successful international clone
causes treatment failure. Antimicrob Agents Chemother 2012,
56(3):1273–1280.
13. Chen CC, Yen MY, Wong WW, Li LH, Huang YL, Chen KW, Li SY: Tracing
subsequent dissemination of a cluster of gonococcal infections caused
by an ST1407-related clone harbouring mosaic penA alleles in Taiwan.
J Antimicrob Chemother 2013, 68(7):1567–1571.
14. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, Kitawaki
J: Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis
2011, 17(1):148–149.
15. Tomberg J, Unemo M, Ohnishi M, Davies C, Nicholas RA: Identification of
amino acids conferring high-level resistance to expanded-spectrum
cephalosporins in the penA gene from Neisseria gonorrhoeae strain
H041. Antimicrob Agents Chemother 2013, 57(7):3029–3036.
16. Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW: Diversity of penA
alterations and subtypes in Neisseria gonorrhoeae strains from Sydney,
Australia, that are less susceptible to ceftriaxone. Antimicrob Agents
Chemother 2007, 51(9):3111–3116.
17. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama
S, Kitawaki J, Unemo M: Is Neisseria gonorrhoeae initiating a future era of
untreatable gonorrhea?: detailed characterization of the first strain with
high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011,
55(7):3538–3545.
18. Gonococcal Isolate Surveillance Project (GISP): U.S. Department of Health &
Human Services - Public Health Service - Centers for Disease Control and Pre-
vention (CDC). CDC; 2010.
19. European Centre for Diseases Prevention and Control (ECDC): Technical
Report. Molecular typing of Neisseria gonorrhoeae. Results from a Pilot Study
2010–2011. Stockholm, 2012. ECDC; 2012.
20. European Centre for Diseases Prevention and Control (ECDC): Surveillance
Report. Gonococcal Antimicrobial Susceptibility Surveillance in Europe, 2011.
Stockholm, 2013. ECDC; 2013.
21. Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T,
Ohnishi M: Antimicrobial Resistance and Molecular Typing of Neisseria
gonorrhoeae Isolates in Kyoto and Osaka, Japan, 2010 to 2012: Intensi-
fied Surveillance after Identification of the First Strain (H041) with
High-Level Ceftriaxone Resistance. Antimicrob Agents Chemother 2013,
57(11):5225–5232.
22. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes
CM: Decreased susceptibility to cephalosporins among gonococci: data
from the Gonococcal Resistance to Antimicrobials Surveillance
Programme (GRASP) in England and Wales, 2007–2011. Lancet Infect Dis
2013, 13(9):762–768.
23. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA,
Van de Laar MJ: Molecular epidemiological typing within the
European Gonococcal Antimicrobial Resistance Surveillance
Programme reveals predominance of a multidrug-resistant clone.
Euro Surveill 2013, 18(3).
24. Martin I, Sawatzky P, Liu G, Allen V, Lefebvre B, Hoang L, Lovgren M,
Haldane D, Caeseele PV, Horsman G, et al: Antimicrobial susceptibilities
and distribution of sequence types of Neisseria gonorrhoeae isolates in
Canada: 2010. Can J Microbiol 2013, 59(10):671–678.
25. Mahon CR, Manuselis G: Textbook of Diagnostic Microbiology. 2nd edition.
Philadelphia, Pennsylvania: W.B. Saunders Company; 2000.
26. EUCAST: European Committee on Antimicrobial Susceptibility Testing - Clinical
breakpoints, Version 3.0, 2013; 2013.
27. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG: Rapid sequence-based
identification of gonococcal transmission clusters in a large metropolitan area.
J Infect Dis 2004, 189(8):1497–1505.
28. Hess D, Wu A, Golparian D, Esmaili S, Pandori W, Sena E, Klausner JD, Barry
P, Unemo M, Pandori M: Genome sequencing of a Neisseria gonorrhoeae
isolate of a successful international clone with decreased susceptibility
and resistance to extended-spectrum cephalosporins. Antimicrob Agents
Chemother 2012, 56(11):5633–5641.
29. Takahashi S, Kurimura Y, Hashimoto J, Uehara T, Hiyama Y, Iwasawa A,
Nishimura M, Sunaoshi K, Takeda K, Suzuki N, et al: Antimicrobial
susceptibility and penicillin-binding protein 1 and 2 mutations in
Endimiani et al. BMC Infectious Diseases 2014, 14:106 Page 10 of 10
http://www.biomedcentral.com/1471-2334/14/106Neisseria gonorrhoeae isolated from male urethritis in Sapporo, Japan. J Infect
Chemother 2013, 19(1):50–56.
30. Balashov S, Mordechai E, Adelson ME, Gygax SE: Multiplex bead
suspension array for screening Neisseria gonorrhoeae antibiotic
resistance genetic determinants in noncultured clinical samples. J Mol
Diagn 2013, 15(1):116–129.
31. Le Lin B, Pastore R, Liassine N, Aramburu C, Sudre P: A new sexually
transmitted infection (STI) in Geneva? Ciprofloxacin-resistant Neisseria
gonorrhoeae, 2002–2005. Swiss Med Wkly 2008, 138(15–16):243–246.
32. Kovari H, de Melo Oliveira MD, Hauser P, Lauchli S, Meyer J, Weber R,
Zbinden R: Decreased susceptibility of Neisseria gonorrhoeae isolates from
Switzerland to Cefixime and Ceftriaxone: antimicrobial susceptibility data
from 1990 and 2000 to 2012. BMC Infect Dis 2013, 13:603.
33. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S: Gonorrhoea treatment
failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011,
16(14).
34. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H: Two cases of
verified clinical failures using internationally recommended first-line cefixime
for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010, 15(47).
35. Unemo M, Golparian D, Hestner A: Ceftriaxone treatment failure of
pharyngeal gonorrhoea verified by international recommendations,
Sweden, July 2010. Euro Surveill 2011, 16(6).
36. Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, Fick D, de Wet J,
Maseko V, Coetzee J, Unemo M: Phenotypic and genetic characterization
of the first two cases of extended-spectrum-cephalosporin-resistant
Neisseria gonorrhoeae infection in South Africa and association with
cefixime treatment failure. J Antimicrob Chemother 2013, 68(6):1267–1270.
37. Unemo M: The 2012 European guideline on the diagnosis and treatment
of gonorrhoea in adults recommends dual antimicrobial therapy.
Euro Surveill 2012, 17(47).
38. Heymans R, Bruisten SM, Golparian D, Unemo M, de Vries HJ, van Dam AP:
Clonally related Neisseria gonorrhoeae isolates with decreased
susceptibility to the extended-spectrum cephalosporin cefotaxime in
Amsterdam, the Netherlands. Antimicrob Agents Chemother 2012,
56(3):1516–1522.
39. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H,
Towns L, Melano RG, Low DE: Neisseria gonorrhoeae treatment failure and
susceptibility to cefixime in Toronto. Canada. Jama 2013, 309(2):163–170.
40. Nakayama S, Tribuddharat C, Prombhul S, Shimuta K, Srifuengfung S,
Unemo M, Ohnishi M: Molecular analyses of TEM genes and their
corresponding penicillinase-producing Neisseria gonorrhoeae isolates in
Bangkok. Thailand. Antimicrob Agents Chemother 2012, 56(2):916–920.
41. Ohnishi M, Ono E, Shimuta K, Watanabe H, Okamura N: Identification of
TEM-135 β-lactamase in penicillinase-producing Neisseria gonorrhoeae
strains in Japan. Antimicrob Agents Chemother 2010, 54(7):3021–3023.
42. Ng LK, Martin I, Liu G, Bryden L: Mutation in 23S rRNA associated with
macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents
Chemother 2002, 46(9):3020–3025.
doi:10.1186/1471-2334-14-106
Cite this article as: Endimiani et al.: Characterization of Neisseria
gonorrhoeae isolates detected in Switzerland (1998–2012): emergence
of multidrug-resistant clones less susceptible to cephalosporins. BMC
Infectious Diseases 2014 14:106.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
